Suppr超能文献

银屑病患者孕期生物制剂安全性的最新进展

Update on biologic safety for patients with psoriasis during pregnancy.

作者信息

Porter Martina L, Lockwood Stephen J, Kimball Alexa B

机构信息

Clinical Unit for Research Trials and Outcomes in Skin (CURTIS), Massachusetts General Hospital, Boston, MA.

Department of Dermatology, Harvard Medical School, MA.

出版信息

Int J Womens Dermatol. 2017 Feb 4;3(1):21-25. doi: 10.1016/j.ijwd.2016.12.003. eCollection 2017 Mar.

Abstract

Biologic agents have become more common to treat patients with psoriasis, but concerns about their effect on pregnancy and lactation often preclude this treatment during these time periods. During the past decade, we have gained a much better understanding of the course of psoriasis during pregnancy and the safety of the use of biologic agents during pregnancy and lactation. Under certain circumstances, biologic agents can be considered appropriate treatment options for patients who are pregnant or lactating.

摘要

生物制剂已越来越普遍地用于治疗银屑病患者,但对其对妊娠和哺乳影响的担忧常常使在这些时期无法采用这种治疗方法。在过去十年中,我们对妊娠期间银屑病的病程以及妊娠和哺乳期间使用生物制剂的安全性有了更好的了解。在某些情况下,生物制剂可被视为妊娠或哺乳期患者的合适治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验